Newark, CA, United States of America

Geunwon Jung

This inventor holds 1 USPTO granted patent. Top assignee: Ultima Genomics, Inc.. Active years: 2026.


% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Geunwon Jung: Innovator in Nucleic Acid Sequencing

Introduction

Geunwon Jung is a notable inventor based in Newark, CA (US). He has made significant contributions to the field of biotechnology, particularly in the area of nucleic acid sequencing. His innovative work has led to the development of methods that enhance the efficiency and accuracy of sequencing nucleic acid molecules.

Latest Patents

Geunwon Jung holds a patent for "Methods of Sequencing Nucleic Acid Molecules." This patent represents a crucial advancement in the field, providing new techniques that can be utilized in various applications, including genetic research and diagnostics. He has 1 patent to his name, showcasing his commitment to innovation in biotechnology.

Career Highlights

Currently, Geunwon Jung is employed at Ultima Genomics, Inc., a company dedicated to advancing genomic technologies. His role at Ultima Genomics allows him to work on cutting-edge projects that aim to revolutionize the way nucleic acids are sequenced and analyzed. His expertise and contributions are invaluable to the company's mission.

Collaborations

Geunwon Jung collaborates with talented professionals in his field, including his coworker Gilad Almogy. Together, they work on innovative projects that push the boundaries of current technologies in nucleic acid sequencing.

Conclusion

Geunwon Jung is a prominent figure in the biotechnology sector, with a focus on nucleic acid sequencing. His patent and work at Ultima Genomics, Inc. highlight his dedication to advancing scientific knowledge and technology. His contributions are paving the way for future innovations in the field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…